论文部分内容阅读
目的探析氨磷汀对合并肝炎的恶性肿瘤化疗患者的肝脏保护作用。方法选择32例合并有乙型肝炎的实体肿瘤患者,将其按照随机原则分为研究组与对照组,各16例,均给予化疗处理,研究组在化疗前先行给予氨磷汀,对照组不予使用,再行对两组化疗前后肝功能的变化情况对比分析。结果两组在肝毒性方面比较,研究组较对照组明显减轻,之间差异在统计学上有显著性(P<0.05),使用氨磷汀的主要不良反应包括呕吐和恶心等。结论对合并有肝炎的恶性肿瘤化疗患者使用氨磷汀具有较好的肝脏保护作用,值得临床予以大力推广应用。
Objective To investigate the protective effects of amifostine on the liver of patients with malignant tumor complicated with hepatitis. Methods Totally 32 patients with solid tumor complicated with hepatitis B were divided into study group and control group randomly according to the principle of randomization. All 16 patients were given chemotherapy. The study group was given amifostine before chemotherapy and the control group did not To use, and then on the change of liver function before and after the two groups of comparative analysis. Results The liver toxicity of the two groups was significantly reduced compared with the control group, the difference was statistically significant (P <0.05), the main side effects of amifostine include vomiting and nausea. Conclusion The use of amifostine in patients with malignant tumor complicated with hepatitis has a good liver protection effect and is worthy to be popularized clinically.